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ABSTRACT 
Engineering Magnetic Viral Nanoheaters for 
Targeted Hyperthermia Treatment of Cancer 
by 
Kelly Horn 
Extensive investigations into the multifunctional nature of magnetic 
nanoparticles have sparked a burgeoning interest in their use for biomedical 
applications. The potential of abolishing cancer via externally induced 
hyperthermia has inspired the development of a plethora of systems used to 
deliver superparamagnetic compounds to cancerous cells while avoiding non-
target tissue. The prevailing challenges are: (A) generating particles capable of 
selectively binding and entering oncolytic targets to generate internal heating and 
(B) delivering adequate amounts of magnetic particles that generate sufficient 
heat at clinically acceptable field levels. Adeno-associated virus (AAV) has yet to 
be exploited as a hyperthermia agent but lends itself well to manipulation as a 
superparamagnetic nanoparticle since it is genetically encoded and can be 
precisely engineered to concomitantly meet multiple aims. Specific aims of the 
project were: (1) endow AAV with superparamagnetic potential through genetic 
engineering, and (2) target virus-metal nanoparticles to cancer cells through 
laboratory directed evolution. 
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SPECIFIC AIMS 
Specific Aim 1: Endow adeno-associated virus (AAV) with 
superparamagnetic (SPM) susceptibility by creating virus-metal hybrids 
• Conjugate iron oxide nanoparticles to lysines on viral capsid 
exterior 
• Biomineralize iron oxide within viral capsid interior via amino acid 
mutations in basic clusters of N-termini 
Specific Aim 2: Target virus-metal nanoparticles to cancer cells via 
laboratory directed evolution 
• Develop mutant viral capsid library via error-prone polymerase 
chain reaction (EP-PCR) followed by staggered extension process 
(StEP) 
• Generate mutant viral capsid library via DNA shuffling 
Specific Aim 3: Develop an in vitro co-culture cell system 
• Stain cancer and normal cells with p16 antibody 
• Sort cells with fluorescence activated cell sorting (FACS) 
CHAPTER 1 
Background & Significance 
1.1 Cellular Heating with Magnetic Nanoparticles 
Magnetic nanoparticles are attractive cellular heating devices due to their 
optimal physical properties, which can be exploited to overcome an assortment 
of problems associated with biological systems. When placed in an 
electromagnetic field, magnetic nanoparticles undergo a realignment of their 
magnetic dipole, converting electromagnetic energy into heat [9] and enabling 
noninvasive manipulation deep within tissue. The intrinsic lack of significant 
paramagnetism within normal tissue [2] offers the advantage of low background 
heating from normal cells not bound to the paramagnetic particle and 
concentrated heating of targeted cells. 
1.1.1 Magnetic Properties of Nanoscale Particles 
As the ratio of the 
number of surface to total 
atoms in a magnetic 
particle approaches 0.5, 
critical chemical and « 
physical changes give 
rise to quantum size 
effects, which lead to 
single domain 
omultidomain 
numerous observable 
Figure 1. Coercivity behavior in magnetic particle systems [3]. 
behavioral changes [10]. Magnetic particles are traditionally multidomain, 
composed of areas of cooperative spins, which are separated by energetically 
favorable domain walls [3]. Beyond some critical diameter (Dc), however, domain 
walls cease to be energetically favored and the particles become single domain. 
Beyond this critical diameter, the coercive field (Hc), the intensity of the magnetic 
field necessary to return the sample magnetization back to zero after a field has 
been applied, theoretically approaches zero as illustrated qualitatively in Figure 
1. Further reductions of the length scale force the particles into the 
superparamagnetic state where thermal fluctuations cause spin rotation to 
replace domain wall motion as the means of reversing magnetization. 
As a magnetic field of strength H is applied to a magnetic material, the 
material responds by displaying its induced magnetization M, which is directly 
proportional to the intrinsic 
magnetic susceptibility of the 
material [2]. In ordered materials, 
this magnetic response is captured 
by the M-H curve that takes on a 
characteristic sigmoidal shape 
(Figure 2). In magnetically 
Figure 2. A general magnetic hysteresis loop [3]. 
irreversible materials, the forward and reverse sigmoidal paths will give rise to an 
open M-H curve termed a hysteresis loop. 
As the nanoparticle diameter is reduced, a widening of the hysteresis loop 
occurs until the superparamagnetic diameter for the material is reached (Figure 
3). A delta function behavior is then observed and the M-H curve collapses into 
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a single sigmoid indicating a 
reversible magnetic response. 
Experimentally, 
superparamagnetism occurs 
When the particles exhibit Figure 3. Magnetic responses associated with 
ferromagnetic and superparamagnetic materials [2]. 
anhysteric measured M-H 
curves and the M-H/T curves measured at multiple temperatures superimpose 
[3]. 
1.1.2 Thermal Destruction of Tumors 
Thermal ablation of tumors becomes possible when tissue temperatures 
are maintained at a minimum of 50°C for at least a few minutes [11] while 
hyperthermic damage occurs when temperatures of at least 42°C for at least 30 
minutes are sustained [2]. Magnetically induced heating mechanisms that will be 
exploited in this proposal to achieve these temperature rises are: (1) hysteresis 
heating and (2) Neel relaxation. Hysteresis losses occur when energy is 
dissipated from the particles during magnetization reversal and can be quantified 
by integrating the area under the M-H curve [11]. The heat generation per unit 
volume is precisely determined according to 
where uo is the permeability of free space = 47rx10"7 TmA"1, f is the frequency of 
the applied magnetic field, H is the applied magnetic field and M is the 
magnetization [2]. 
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Magnetic particle magnetization will relax to zero upon removal of an 
applied magnetic field due to flipping of the atomic magnetic moments (Neel 
relaxation) and/or particle rotation (Brownian relaxation) [2]. Superparamagnetic 
particles fixed via conjugation or attachment to the outer or inner viral surfaces 
will be prohibited from exhibiting Brownian relaxation and, thus, Neel relaxation 
will dominate. Neel relaxation losses will occur due to the fluctuating of the 
magnetic moment across an anisotropy barrier and are associated with a 
characteristic relaxation time T„ given by 
TV, = 7-0exp(^), 
where AE is the anisotropy energy barrier, kT is the thermal energy and the pre-
exponential factor is often approximated to be T0~ 109 sec"1 but actually depends 
on parameters such as particle anisotropy, temperature and saturation 
magnetization [10, 12]. Knowledge of the exact value of the pre-exponential 
factor is unnecessary since the equation is dominated by the exponential term. 
Since the energy barrier is equal to the product of the anisotropy constant 
and the volume (KVV) of a given particle, rn is heavily dependent on particle size, 
with small decreases in size forcing substantial decreases in relaxation time. For 
instance, consider spherical magnetic particles where TQ = 10"9 sec, Kv = 105 Jm"3 
and T = 300K; a decrease in diameter from 14.6 to 11.4 nm would force rn from 
108 to 0.1 seconds [3]. For larger particles, the measurement time (rmeas) « rn 
and a change in the external magnetic field does not cause a new magnetic 
equilibrium state [10]. For very small superparamagnetic particles, however, 
rmeas » Tn and the particles respond to the external field with a new equilibrium 
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magnetization during the time of measurement. If 7meas = rn, the system is 
blocked and the particles do not relax during the measurement time. 
The physical basis of heat generation from SPM particles is the power 
dissipation that occurs according to the first law of thermodynamics, which 
dictates that magnetic work will be converted into internal energy when M lags H 
[13]. Heat is generated according to the equation 
PSPM = Mo/rfx'H2 
where PSPM is the volumetric power dissipation of the SPM particle in Wm"3, u0 is 
the permeability of free space = 47ix10"7 TmA"1, f is the frequency of the applied 
magnetic field, x" is the frequency dependent out-of-phase magnetic 
susceptibility component and H is the magnetic field intensity. Heat generation 
measurements are typically reported as a specific absorption rate (SAR) in Wg'1, 
which can be found by dividing PSPM by the density of the particles [2, 11]. 
Ultimately, the frequency and strength of the applied magnetic field will 
dictate the heating capacity of individual SPM particles and the overall hysteresis 
behavior of ferromagnetic particles. However, high frequency magnetic fields 
lead to deleterious physiological effects such as skeletal and cardiac muscle 
stimulation [14, 15]. Experiments have determined that frequency and amplitude 
ranges of 0.05-1.2MHz and 0-15kAm"1 are clinically acceptable [2]. Under these 
operational constraints, ferromagnetic materials fall short of delivering their 
maximal heating capacity in biological hyperthermia applications due to 
unsaturated hysteresis loops, which result in low operational SARs. SPM 
particles, however, can generate much higher SARs at clinically acceptable 
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frequencies, making them the optimal choice for physiological heating. This 
proposal will exploit the benefits of superparamagnetic heating by engineering 
single domain biocompatible viral nanodevices. 
1.1.3 Current Non-viral Magnetic Nanoparticie Platforms 
Small particle hyperthermia was first proven plausible in 1957 when 
Gilchrist et al demonstrated successful lymph node heating with maghemite 
particles [16]. Since then, the viability of using localized heat generation to cause 
deleterious effects in tumor cells has been established via direct injection into 
cells [17-20]. Unfortunately, two main challenges have greatly hindered 
widespread clinical use: (1) generating particles capable of selectively binding 
and entering oncolytic targets such that heat is generated internally [21-23] and 
(2) delivering adequate amounts of magnetic particles that generate sufficient 
heat at clinically acceptable field levels [2, 21]. 
Researchers have previously conjugated antibodies to liposome 
encapsulated and pure magnetite particles in efforts to selectively target antigens 
on cancer cell surfaces [19, 24-26] and have attached macromolecules to viral 
surfaces to endow them with new functions, which effectively allow for the 
retargeting of the viruses [27]. However, these methods heavily rely on 
imprecise covalent modifications of the magnetic nanoparticles and prior 
knowledge and existence of receptor-ligand pairs on the cell surface for success. 
Attempts have also been made to localize the magnetic therapeutic to tumor cells 
using magnets [28], but this approach requires prior knowledge of cancer cell 
locations and often damages healthy surrounding tissue as well. Recent efforts 
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to use synthetic routes to **»**• 
XX Co 
create a library of surface- ° 
modified magnetic ^ ° ' ^ 
nanoparticles, which can be 
screened for a biological target, 
have shown limited success in 
overcoming current selectivity 
difficulties with undesirable 
non-target 
Amines 
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binding Figure 4. Examples of the types of molecules 
conjugated to the nanoparticle to generate the 96 
accompanying the increased member library [6]" 
binding affinity for targets [6]. Whereas this library produced 96 members (Figure 
4) from which the most biologically fit clone could be selected, virus-metal 
libraries would far surpass this number, allowing for a sampling space with 
millions of possible variants without a priori knowledge of the target features. 
Since the phenotypic fitness of virus-metal clones is genetically encoded, the 
reproducible generation of highly selective particles is possible through 
exploitation of the genotype-phenotype link. 
The vast majority of magnetic hyperthermia studies focus on the use of 
iron oxides in the magnetite (Fe304) or maghemite (Y-Fe203) forms due to their 
demonstrated biocompatibility within the body and large magnetic susceptibilities 
[2]. Most early magnetic hyperthermia work centered on using high 
concentrations of magnetite particles to exploit hysteric heating. The revelation 
that relaxation effects allow single domain particles to absorb more power than 
multidomain hysteric systems at biologically tolerable magnetic fields tipped 
scientific interest away from ferromagnetic systems and towards magnetic fluid 
hyperthermia [2]. Further discoveries that single domain particles are not just 
capable of producing individual hot spots but exhibit temperature homogeneity 
solidified movement towards using single domain particles to overcome heating 
challenges. Since single domain particle hyperthermia is still in its infancy, AAV 
holds great promise as a scaffold for monodisperse particle synthesis and 
selective metal delivery to cancer cells. 
1.2 AAV as a Molecular Targeting Modality 
1.2.1 Adeno-associated Virus (AAV) 
AAV is a &. rep cap on i -
non-pathogenic Figure 5. AAV genome. 
helper-dependent virus with a 4.7 kb, single-stranded genome. This packaged 
genetic material contains two open reading frames, rep and cap flanked by 
inverted terminal repeats (ITRs) (Figure 5) inside a capsid [29, 30]. Cap encodes 
for three proteins, VP1, VP2 and VP3 that self-assemble to form the capsid while 
rep encodes for four proteins, which aid in the 
replication of the viral genome. AAV serotype 2 is 
the most widely studied of the AAV serotypes, and 
its atomic structure has been determined by x-ray 
crystallography and electron cryo-microscopy [7, 
31]. AAV2 infects cells by binding to heparin 
sulfate proteoglycan and entering through clathrin- Figure 6. AAV capsid [7]. 
coated vesicles [32]. 
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The icosahedral AAV capsid diameter is approximately 25 nm and is 
composed of 60 subunits of VP1, VP2 and VP3 (Figure 6), which exist in an 
approximate ratio of 1:1:10. While the three proteins share a C-terminus, the N 
termini of VP 2 and 1 extend 
from the end of VP3 an 
leoe* VP1 
BC1 BC2 BC3 
122-124 )37-i44 leH-iia W/" 
additional 65 and 203 amino +H-,N| 
acids, respectively (Figure 7). 
The VP1 N-terminus also 
•r^ri'ir-
*wp|H GQ&VP2 
contains a phospholipase A2 Figure7.VP1-3N-termini[8]. 
(PLA2) domain, which is initially packaged inside the capsid but is exposed 
during infection [31, 33]. Three basic amino acid clusters (BC), BC1, BC2 and 
BC3, are also located on the VP1 N-terminus while only BC2 and BC3 are found 
on the VP2 N-terminus (Figure 7). Evidence suggests that the N-terminal 
extensions of VP1 and VP2 are located inside the capsid at the two-fold 
symmetry axes [33]. During AAV2 infection, the VP1A/P2 N-termini containing 
the BC domains are exposed through the virus capsid pores. There are 12 pores 
surrounding the five-fold symmetry axes, which are narrowest on the outer 
surface with a diameter of -0.8 nm and widen toward the interior with a diameter 
of 1.6 nm [31]. Upon exposure, the BC domains normally function as nuclear 
localization signals in the cytoplasm. When mutated to acidic residues to induce 
iron oxide nucleation, this functionality will likely be lost due to confinement inside 
the capsid and mutation of the positively charged amino acids responsible for the 
activity. 
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1.2.2 Directed Evolution of A A V 
Rational Design 
The rational design approach to protein engineering is accomplished 
through introduction of mutations at specific molecular sites, which are chosen 
based on prior knowledge of their structure and function [34]. Amino acids are 
substituted, inserted or deleted often via site directed mutagenesis (SDM) at sites 
pre-selected by the researcher based on prior knowledge of genotype-phenotype 
links. Since this approach relies heavily on human input, it is highly directed, and 
information regarding the protein's 3D structure and activity is needed [34]. 
Rational design, therefore, has limited applicability because it is information 
intensive and many proteins are not well characterized enough for the success of 
this approach. 
Multiple efforts to retarget AAV vectors and study their tropism through 
rationally guided approaches have been undertaken. A single lysine to 
glutamate change from AAV1 to AAV6 is enough to ablate heparin binding ability, 
indicating that one amino acid residue can tip the surface electrostatics and alter 
viral tropism [35]. Additional studies have demonstrated potential for retargeting 
AAV through insertions of nonviral ligand sequences into the viral capsid [36]. 
Creative attempts to cross-package the AAV2 genome in other capsid serotypes 
[37] and make AAV mosaics with ligand insertions [38] have shown success, 
imparting vectors with altered tropisms. While these approaches have been 
successful, incomplete knowledge of complex target cell features often makes 
12 
rational methods impossible to implement, giving rise to the need for directed 
evolution approaches. 
Error-Prone Polymerase Chain Reaction (EP-PCR) & Staggered Extension 
Process (StEPV 
1 £. 
EP-PCR is the 
most commonly used 
tool to introduce 
random mutations in a 3 
gene, creating a library M " 
of genetic variants. The 
library can be subjected 
to selection/screening 
to identify mutants with 
improved fitness for a 
particular function [39]. Figure 8. TheStEP process, (adapted from [5]) 
StEP is a technically simple yet effective method of in vitro recombination that 
relies on the preparation of full-length genes from templates (Figure 8) [5]. Step 
1 illustrates the denatured parent templates that are primed with the initial primer. 
Step 2 shows the output of the first round of polymerase-catalyzed primer 
extension. After step 2, the template and elongated fragments are denatured, 
allowed to re-anneal randomly and finally elongate through the template 
switching process. Step 4 represents the continual repetition of this process until 
the final product is formed in Step 5. A strength of this method is that at each 
13 
cycle, the elongating fragments can anneal to a different parent sequence and be 
extended by short lengths, thereby allowing for very closely spaced mutations to 
be efficiently recombined. 
EP-PCR has been used alone [40] or in combination with StEP [41] to 
engineer vectors capable of evading antibody neutralization. Since the majority 
of the human population has antibodies against AAV2, vector use for biomedical 
applications is limited because neutralizing antibodies block successful delivery 
of cargo. In both cases, 2-3 nucleotide mutations in two different amino acids 
were responsible for the increased clonal fitness. In addition, an EP-PCR with 
StEP library was used to select for viral mutants with increased or decreased 
affinities for heparin [41]. Since these approaches demonstrate the plausibility of 
retargeting AAV2's natural binding affinity, they indicate promise for the directed 
evolution of AAV towards cancerous cell targets. 
DNA Shuffling 
DNA shuffling refers to the process through which multiple parent DNA 
sequences are randomly cut with DNase I, mixed, and subsequently 
reassembled into new chimeric sequences by PCR [42] (Figure 9). To increase 
the diversity of the library, mutations can also be introduced during the 
reassembly process. These new sequences are then denatured, annealed 
based on sequence homology and extended to obtain products with 
combinations of more than one parental sequence, thus presenting researchers 
with a powerfully efficient means of generating chimeric genes. As shown in 
Figure 9, the process starts with multiple parent sequences, which are non-
14 
Parent gates to be shuffled 
31—II—IE 
3C3C 
3C3C 
Cycles of denaturation-
annealtng-extension 
denatured 
fragments 
I ^ annealing. 
3 • ' 
tm extension 
denaturation 
I Amplification of futHength 
I sequences 
specifically cut with DNase I. 
These fragments then enter a 
cycle where the double strands 
are denatured into single 
strands, allowed to anneal based 
on sequence homology, and 
finally extended via polymerase 
to obtain the end product. 
AAV DNA family shuffling, 
where the capsid genes of 
multiple AAV serotypes are 
Shuffled, has recently been applied Figure 9. The DNA Shuffling method [1]. 
in conjunction with a peptide display library to optimize AAV as a vector for 
therapeutic liver transduction [43]. DNA family shuffling was shown to have 
superior diversity, complexity and versatility over other directed evolution 
methods reported to date and retargeted clones were successfully identified. 
Another group successfully used DNA shuffling of AAV serotypes 1-9 to engineer 
a capsid capable of transducing melanoma cells that were previously resistant to 
AAV transduction [44]. 
Peptide Display 
Peptide display is a method of directed evolution where random peptides 
can be inserted in a rationally determined region to alter or improve a pre-existing 
function. Insertion of a random seven amino acid peptide after amino acid 
15 
position 587, which is one of the residues responsible for heparin binding by 
AAV2, have been shown to retarget the vector [45, 46]. Both a human 
megakaryocyte cell line and a lymphocytic leukemia cell line, which were 
previously resistant to AAV infection, were infected with retargeted vector [45]. 
Peptides were also identified that had the ability to enhance transduction in 
coronary endothelial cells as compared to non-endothelial controls [46]. 
1.3 Potential of AAV as Virus-Metal Agent 
Recent interfacing between the fields of virology and biomimetic chemistry 
has given rise to many attempts to emulate the precise nanosynthesis seen in 
natural biological systems. Researchers have used cowpea mosaic virus 
(CPMV) crystals as scaffolds for metal growth [47], entrapped organic polymers 
and inorganic minerals inside cowpea chlorotic mottle virus (CCMV) [48], 
selected for peptides that nucleate inorganic materials [49] and directed the 
synthesis of semiconducting nanowires [50]. These previous manipulations of 
viral scaffolds indicate promise for the use of AAV as a metal delivery agent. 
1.3.1 Natural Biomineralization of Iron Oxide 
Although the nucleation of iron oxide inside viral capsids is synthetic, the 
biomineralization of iron within protein scaffolds naturally occurs in most 
organisms. Ferritins are iron storage proteins found in a range of organisms from 
bacteria to frogs, horses and even humans [4] that exhibit stability over pH 
ranges of 2-10 and temperatures up to 70°C [51]. Apoferritin molecules are 
hollow protein shells with inner and outer diameters of 8 and 12 nm, respectively, 
which form when 24 subunits of H and L (heavy and light) ferritins with about 
16 
55% sequence homology self-
assemble [52] into the structure 
shown in Figure 10. The H chain 
contains ferroxidase sites that 
catalyze the oxidative hydrolysis of 
iron whereas the L subunit contains 
glutamate residues that are believed 
to be responsible for creating a 
microenvironment conducive to Figure 10. Apoferritin molecule [4]. 
mineralization [4]. It is believed that iron enters the preformed cage via threefold 
channels in the shell and is electrostatically guided to the oxidation center on the 
interior protein surface. Subsequent autocatalytic oxidative hydrolysis occurs at 
the site of the formed mineral core until the iron oxide reaches the cage walls, 
constraining further growth. This natural ferritin synthesis was recently mimicked 
using the interior charge of a bacterial ferritin-like protein (FLP) to nucleate the 
iron oxide, maghemite, inside the protein [53]. 
1.3.2 Plant Viruses as Biotemplates for Iron Oxide Synthesis 
Plant virus interiors provide size constrained vessels that are amenable to 
modifications that can nucleate iron oxide growth [54]. Researchers have 
recently reprogrammed brome mosaic virus self-assembly by forcing the cavity 
diameter to expand to accommodate iron oxide nanoparticles that were larger 
than the biological cavity [55]. Tobacco mosaic virus (TMV) was used to 
mineralize iron oxide on the outer surface of this rod-like virus [56]. CCMV 
17 
protein cavities have been synthesized without viral RNA and genetically altered 
to nucleate iron oxide formation inside the capsid [53]. In this work, the natural 
positive charge of the interior surface was changed to negative by mutating the 
180 N-terminal basic lysine (3 per N-termini) and arginine (6 per N-termini) 
residues to glutamic acids, which allowed iron cations to bind and form a mineral 
core via electrostatically driven oxidative hydrolysis. Since plant and mammalian 
viruses share many common features, a similar rationally designed approach to 
iron oxide mineralization within the AAV capsid lumen is promising. 
18 
CHAPTER 2 
MOTIVATION AND METHODS 
2.1 Endow adeno-associated virus (AAV) with superparamagnetic (SPM) 
susceptibility by creating virus-metal hybrids 
One of the greatest challenges facing researchers designing biomedical 
nanomachines is the biocompatibility and immunogenicity of these constructs. 
Since at the most basic level, viruses traverse complex biological barriers, infect 
cells, and deliver genetic material, mammalian viral evolution has provided 
nanochemists with protein templates that lend themselves well to overcoming 
this hurdle in biomedical applications. Because humans are a natural host for 
AAV, these viruses have evolved to survive in the exact extracellular 
environment that in vivo metal delivery agents would have to face. Adeno-
associated viral nanotemplates are genetically encoded in a simple genome that 
can be easily manipulated to concomitantly meet multiple aims with one 
nanodevice, which can then be reproduced with impressive monodispersity. 
AAV presents a viable backbone for delivering large quantities of iron oxide to 
the cancer cells via (1) attachment of iron oxide nanoparticles to the 480 
chemically addressable lysines on the viral capsid surface and (2) nucleation of 
iron oxide crystals in the viral cavity, which provides approximately double 
possible payloads of iron oxide per protein cage than the natural biological 
counterpart, ferritin. 
2.1.1 Conjugate iron oxide nanoparticles toAAV2 capsid surface 
19 
A conjugation between the surface exposed lysines on the AAV2 capsid 
surface and the carboxyl groups on the magnetic nanoparticles was planned via 
a two-step chemical reaction (Figure 11). The magnetite (Fe304) particles 
synthesized via co-precipitation by our collaborator, Kung-Po Chao in Dr. Lisa 
Biswal's laboratory (Department of Chemical Engineering, Rice University), were 
surface carboxylated with polyacrylic acid. In the presence of the carbodiimide, 
1-ethyl-3-[3-dimethylaminopropyl]carbomiimide (EDAC), the carboxylated 
magnetic nanoparticles form a reactive ester intermediate [57] (Step 1 of Figure 
11). In the presence of N-hydroxysuccinimide (NHS), this amine reactive ester is 
amenable to crosslinking with the lysine groups on the AAV2 surface either 
directly via path 1 or through a sulfo-NHS ester intermediate as in path 3 (Figure 
11). Some product resists the conjugation and returns back to its original stable 
form (path 2 of Figure 11). The reaction is performed in 2-
[morpholinojethanesulfonic acid (MES) buffer, which is a saline based activation 
buffer maintained at a pH of 6.0. 
After the conjugation proceeds under continuous vortexing for 3 hours, the 
reaction is placed on a magnet overnight, forcing the magnetic particles and the 
virus-particle conjugates to pellet. The supernatant is discarded, and the pellet is 
resuspended in water. This sample is then heat treated for 30 minutes at 75°C, 
which leads to denaturation of the capsid and genome release, and subjected to 
Q-PCR, which identifies whether any viral particles were in the supernatant. If 
viral genome levels exceed background, a Western blot is performed on the 
20 
remaining supernatant to verify the presence of the three viral proteins, VP1-3, 
indicating that capsid was attached to the magnetic nanoparticles. 
Figure 11. Schematic of conjugation between carboxyl groups on the magnetic nanoparticles and 
amine groups on AAV2. 
2.1.2 Biomineralize iron oxide inside capsid lumen via oxidative hydrolysis 
AAV2 Table 1. Viral mutations from wild-type are shown in red 
capsids were 
genetically modified 
to mimic the natural 
iron storage protein, 
ferritin, by 
employing an approach similar to the one used to make CCMV interiors capable 
of sequestering maghemite [53]. To make the capsid interior conducive to 
spatially constrained oxidative hydrolysis of iron oxide while maintaining 
structural integrity of the capsid, the positively charged arginine and lysine 
Viral Clone 
wtAAV2 
mBC1 
mBC1,2 
mBC1,2,3 
BC1 
kkr 
eee 
eee 
eee 
BC2 
ktapgkkr 
ktapgkkr 
etapgeee 
etapgeee 
BC3 
kagqqparkr 
kagqqparkr 
kagqqparkr 
eagqqpaeee 
Net Charge A 
per capsid 
0 units 
15 units 
50 units 
90 units 
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residues present in the basic clusters of VP1 and VP2 N-termini were mutated to 
negatively charged glutamic acid residues. I generated three viral mutants with 
varying degrees of electrostatic charge change inside the capsid, which will be 
the driving force for nucleation (Table 1). Mutants BC1, BC1.2 and BC 1,2,3 
were mutated in the indicated BC domains leading to charge changes of 15, 50 
and 90 units per capsid, respectively. The overall consequence of the mutations 
is the conversion of the interior of the capsid from cationic to anionic. I 
hypothesize that this electrostatic change could be a driving force for iron oxide 
nucleation inside AAV2 on the VP1/VP2 N-termini. 
Mutant BC constructs were made into viruses via double transfection of 
293T cells with pXX6, a helper plasmid, and the respective BC plasmid or 
prepcap, which contains rep and cap ligated into pBluescript at the Xba\ sites, as 
a control. These mutant viruses were then screened for capsid assembly to 
ensure basic viral functions were conserved. Capsid integrity of the mutants was 
checked with a dot blot using the A20 antibody for detection of intact capsid and 
a Western blot using the B1 antibody to detect the existence of the three viral 
proteins, VP1-3. The A1 antibody epitope, which is in the VP1 N-terminus 
(aa123-131), was destroyed in all the BC mutants and should not be detectable 
via dot blot analysis in either room temperature or heat treated (denatured) 
samples. The A69 antibody epitope, which is in VP1 and VP2 N-termini (aa169-
184 of VP2 & less strongly aa123-136 of VP1), should be weaker than wild-type 
but still detectable in dot blot analysis after heat treatment at 75°C in BC1 and 
BC1.2. 
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The characterized mutant capsids could serve as future templates for the 
spatially constrained formation of iron oxide, as iron ions traverse through the 
pores and nucleate at the N-
termini. Two chemical 
routes of oxidative 
hydrolysis using ferrous 
ammonium sulfate 
[(NH4)2Fe(S04)26H20] as 
the Fe2+ source could be 
attempted with either air (O2) 
or hydrogen peroxide (H2O2) "% * ft 
as the oxidant (Figure 12). Figure 12. Possible oxidative hydrolysis routes. 
Special care should be taken to ensure at least 200 atoms/capsid are added to 
avoid undesirable Fenton reactions, which produce hydroxyl radicals when Fe2+ 
mixes with H2O2 in solution [4]. Reaction conditions such as pH and temperature 
should be optimized to obtain iron oxide particles of the maghemite and 
magnetite forms. Particles could be stained with uranyl acetate and imaged with 
transmission electron microscopy TEM to verify nucleation in the capsid lumen. 
2.2 Target virus-metal nanoparticles to cancer cells via laboratory directed 
evolution 
While rational approaches to retargeting AAV vectors can lead to 
improved selectivity, they often rely on incomplete knowledge of receptor targets 
and can lead to unacceptable levels of non-target cell binding. Directed evolution 
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approaches, on the other hand, seek to emulate natural mutagenic evolution and 
recombination to create libraries of variants that can be selected/screened for 
desired properties. This proposal suggests the use of in vitro directed evolution, 
the process through which repeated cycles of mutagenesis and selection will 
force the evolution of the cap sequence towards the desired tropism, as a means 
of improving selectivity for target cells over levels obtainable with rational 
approaches. The two approaches proposed here are (1) error-prone PCR and 
(2) DNA shuffling. Success in overcoming limitations associated with rational 
design of AAV has been shown with peptide display [45, 46], EP-PCR alone [40] 
or combined with StEP [41] and DNA shuffling [43, 44] libraries. Directed 
evolution of virus-metal particles offers tremendous potential toward overcoming 
current selectivity difficulties in hyperthermic treatments while providing a 
genetically encoded nanodevice that is amenable for further modification to meet 
other potential design objectives. 
2.2.1 Error-prone PCR & StEP Library 
The first library was generated using error-prone (EP) PCR on the AAV2 
cap gene [58]. Since the AAV2 cap gene encodes for the proteins of interest, 
VP1-3, this genetic sequence was the input for the library creation process. The 
AAV2 cap sequence was first mutated and amplified via EP-PCR using Taq DNA 
polymerase and a pSub201 template, which contains rep and cap flanked by 
ITRs and an ampicillin resistance gene. Since infidelity is desirable and trumps 
amplification efficiency in this type of PCR, reaction conditions were chosen such 
that the cumulative error rate of the polymerase over multiple cycles yielded 
desired mutation frequencies without mutational biases. Taq DNA polymerase 
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was chosen over other thermostable polymerases because it has the highest 
natural error rate of 0.1-2x10"4 errors per nucleotide per polymerase pass [59]. 
Since this error rate is insufficient to generate a library with functional diversity, 
manganese chloride (MnCb) was used to complement Taq's natural promiscuity 
[39]. Optimal MnCb concentrations were considered those that gave mutation 
frequencies of ~ 2-5 base changes per gene [1]. Higher mutation rates skew 
one's ability to accurately determine true genotype-phenotype links since the 
influence of single point mutations are difficult to gauge. Additionally, as the 
number of nucleotide substitutions increases, the probability of obtaining mutants 
that will fold to the natural protein structure decreases exponentially [60]. To 
overcome Taq's natural mutational bias towards AT to GC changes, an 
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Figure 13. psub2-spe cloning scheme. 
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unbalanced nucleotide mixture with slightly higher concentrations of dGTP and 
dATP than dTTP and dCTP was used [61]. 
The PCR products with HindWl and Spel ends were subsequently ligated 
with pSub2-Spe, a vector I generated containing rep, the ITRs, an ampicillin 
resistance gene and HindlW & Spel sites (Figure 13) and transformed into 
XUOGold bacteria to generate the plasmid library. The calcium phosphate 
precipitation method could be used to package the viral library in mammalian 
cells. The viral library could then be selected for mutant AAV2 capsids with a 
high affinity for cancer cells and low levels of normal cell binding. 
StEP, a technique that utilizes template switching to yield full length genes 
via recombination of fragments from a pool [5], could then be performed on the 
mutants with the desired tropism to evaluate the cumulative effects of each of the 
favorable mutations and identify the fittest combination. The EP-PCR primers 
could be used with Vent DNA polymerase and an equimolar ratio of dNTPs in the 
reaction. The StEP products could then be ligated into pSub2-spe and 
transformed into electrocompetent bacteria to generate a new plasmid library. 
This library could once again be packaged into 293T cells, and subjected to 
selection and screening. 
2.2.2 DNA Shuffling Library 
Nature has provided numerous AAV serotypes with both homologous and 
non-homologous regions that lead to shared similarities but also stark 
differences, including varying tropisms. Using the products of natural evolution 
as a diverse pool of starting variants, this method seeks to recombine partial 
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fragments of the cap genes from AAV serotypes 1-11. This library development 
was started in collaboration with Kellie McConnell, another graduate student in 
Dr. Suh's laboratory. First, the cap genes from each serotype were amplified via 
PCR with primers that introduced HindlW and Spel at the 5' and 3' ends, 
respectively, which was subsequently cloned into pBluescript cut with Hind\\\ and 
Spel. The pBluescript-cap constructs were then digested with Bgl\\ and Pvu\ to 
generate the parent genes for shuffling, which consist of the 2.6 kb cap gene 
flanked on either side with an extra -150 bp buffer zone to allow for undesirable 
exonuclease activity during reassembly. These fragments could then be 
randomly digested with DNasel to generate a pool of fragments, which would 
become the input for PCR. Through cycles of denaturation, annealing and 
extension, recombination based on sequence homology would reassemble the 
fragments, which would be subsequently amplified into full-length cap genes 
flanked by HindlW and Spel sites via PCR. The PCR product would then be 
cloned back into the pBluescript backbone with HindWl and Spel sites. 
2.3 Develop an in vitro co-culture system 
Electromagnetic fields can penetrate to the depths of any part of the 
human body, enabling noninvasive manipulation deep within tissue [2]. The 
conversion of electromagnetic energy into heat in the presence of an alternating 
magnetic field allows for the possibility of externally triggered heating in any 
organ. The intrinsic lack of significant superparamagnetism within normal tissue 
offers the advantage of low background heating from normal cells not bound by 
iron oxide nanoparticles and concentrated heating of targeted cells. It is only 
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possible to test this heating from a distance if an in vitro co-culture cell system is 
first developed. 
Both the virus-metal conjugates and the virus-metal nucleated products 
will ultimately need to be tested for their heating ability in bulk solution. 
Magnetite (Fe304) and maghemite (Fe203) have Dc values of 128 and 166 nm, 
respectively [3], which means that individual members of both of the virus-metal 
nanodevice populations created will be single domain, primarily generating heat 
via relaxation effects. However, the combinatorial heating effects of the particles 
in solution will ultimately need to be determined since particle size polydispersity 
and internal anisotropy will ultimately dictate heating capacity. Magnetic fields 
with frequencies and amplitudes in the ranges of 0.05-1.2 MHz and 0-15 kAm"1, 
respectively, should be tested and temperature changes in the cell solutions 
should be measured. 
2.3.1 Co-Culture for Selection & Heating of retargeted virus particles 
After the 
plasmid library is 
transfected into 293T 
cells for viral 
production (step 1, 
Figure 14), the viral 
library will need to be 
selected for clones 
that selectively bind 
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library Into producer 
cells 
2. Obtain diverse 
virus library 
3. Infect target & 
nontarget cells 
4. Sort GFP-expressing 
cancer cells 
5. Amplify positive 
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6. Repeat selection 
•^ Plasmid library 
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viruses 
•< Virus nanoparticles able to 
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Figure 14. Future viral nanoparticle selection on co-culture. 
28 
cervical cancer cell targets. This selection step will need to be performed on a 
co-culture of cancerous HeLa cell targets and normal human dermal fibroblast 
(NHDF) non-targets. The HeLa cells will need to be engineered to stably 
express green fluorescent protein (GFP) by lipofectamine transfection of a GFP 
plasmid with kanamyicin resistance. G-418 sulfate antibiotic can be used to 
select for cells expressing GFP. After application of the viral library to the co-
culture, the cells could be sorted into target and non-target populations using 
fluorescence activated cell sorting (FACS), superinfected with adenovirus 5 (Ad5) 
to amplify clones and lysed to rescue the genomes. PCR could then be used to 
recover viral cap sequences of the mutants infecting the target and non-target 
cell types. 
Isolated cap clones could then be made into viruses via triple transfection 
of 293T cells with pXX6, pAV2-LacZ and psub2-spe ligated with the isolated 
mutant cap. These identified mutant viruses could then be screened for capsid 
assembly and genome packaging to ensure the tropism modifications conserved 
basic viral properties. Capsid integrity could be verified with a dot blot, which 
uses the following antibodies: (1) A20 for detection of intact capsid and (2) A1 to 
detect VP1 N-terminus and A69 to detect VP1 and VP2 N-termini exposure upon 
heat treatment at 75°C. Genomic and capsid titers could be determined with Q-
PCR and an enzyme-linked immunoabsorbant assay (ELISA), respectively, and 
divided with an expected outcome ratio of 1, which would verify that each virus 
capsid packages one genome. 
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CHAPTER 3 
Results & Discussion 
3.1 Creating virus-metal hybrids 
Magnetite (Fe304) nanoparticles were synthesized, carboxylated with poly-
Figure 15. Magnetite particles Figure 16. Magnetite Particle Distribution, 
imaged with TEM. 
(Courtesy of Kung-Po Chao) 
acrylic acid and imaged with TEM by our collaborator, Kung-Po Chao, in Dr. Lisa 
Biswal's laboratory (Figure 15). These particles have an average diameter of 
34.3 nm with the distribution determined by dynamic light scattering and shown in 
Figure 16. We tried the NHS chemistry based conjugation scheme a few times. 
Molar ratios of amino to carboxyl groups of 1:1, 1:2, 1:4 and 1:8 were attempted. 
Our first attempt utilized two 3000 Gauss magnets to pull down the magnetic 
particles after the reaction but no pellet was observable after 12 hours and 
QPCR results yielded viral genome counts equivalent to background levels in the 
reaction, indicating the conjugation was unsuccessful. The conjugation was 
reattempted with two 5000 Gauss magnets and a 10-fold greater amount of 
magnetic particles but still failed to yield an observable pellet. Alternative 
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methods for isolation of the magnetic particles, such as ultracentrifugation, could 
be explored in the future. 
25°C 
75°C 
prepcap 
BC1 
BC1.2 
BC 1,2,3 
prepcap 
BC1 
BC1.2 
LBC 1,2,3 
25°C^ 
75°C^ 
A20 
A69 
25°C 
75°C 
25°C 
75°CH 
Figure 17. Dot blot analysis with A20 (a), A1 (b), A69 (c) and B1 (d) antibodies. 
I constructed the plasmids for generating BC1, BC1.2 and BC1,2,3 
mutants from prepcap using site-directed mutagenesis, as detailed in Table 1, 
and verified the mutations through sequencing. A double calcium phosphate 
transfection method with pXX6 as a helper plasmid was performed to generate 
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the viral mutants in 293T cells. I then characterized the mutants by performing a 
dot blot with A20, A1, A69 and B1 antibodies (Figure 17). 
The A20 antibody results showed that only mBCI had intact capsid. This 
could be because the titers of the other virus preparations were too low to be 
detectable via dot blot analysis. Alternatively, the titer of the prepcap preparation 
could have been below a detectable level, and one of the mutations common to 
the mBC1,2 and mBC1,2,3 mutants disrupted capsid formation. As expected, A1 
antibody results showed no detectable signal for any of the constructs. A69 
antibody results provide further evidence for the hypothesis that prepcap has a 
low titer while a mutation introduced in mBC1,2 disrupts normal viral function 
since only mBC1 shows a detectable signal. B1 antibody results concur with the 
other stains, indicating that only denatured capsid from mBC1 was detectable. 
3.2 Generating directed evolution libraries 
I have constructed pSub2-spe, 
which contains the ITRs, ampicillin 
resistance gene and rep with Hind\\\ and REP-
Spel sites for insertion of the cap library 
(Figure 18). The starting material for the I psub2-spe 
• 5762 bp 
vector creation was prepcap, which was 
made by Kellie McConnell and consists 
of a pBluescript backbone with rep and - _._^ . „ 
"" AmpR 
Figure 18. Map of the psub2-spe cloning vector. 
cap cloned in at the Xba\ sites. To 
create pSub2-spe, I first knocked out the Spel site from the pBluescript backbone 
Spel(5675) 
Hindni(5669)_ 
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and inserted a Spel site at the end of the cap gene. A Hind\\\ site was then 
added before Spel at the end of cap to facilitate future removal of the wild-type 
cap region (Step 1 in Figure 13). Prepcap and pSub201 were then digested with 
Xba\ and ligated together to generate pSub2-spe with a wild-type cap gene 
flanked by Hind\\\ sites (Step 2 in Figure 13). This new vector was digested with 
Hind\\\ and religated on itself, resulting in pSub2-spe. 
I have successfully constructed and analyzed the first bacterial EP-PCR 
EP-PCR Trend 
1 
I 
I 
0.00 
0.1 0.15 0.2 0.25 0.3 0.35 0.45 0.5 1 
[MnCI2](mM) 
Figure 19. EP-PCR library yields Figure 20. EP-PCR product yield quantification. 
with increasing MnCI2 
concentrations. 
library and analyzed the mutation frequency associated with the MnCb 
concentrations. The EP-PCR products generated from an identical master mix 
with varying [MnCb] were Zymo kit purified and 10 uL were run on a 1% agarose 
gel (Figure 19). The PCR yields were quantified by measuring the band intensity 
for each of the libraries and normalizing to the lowest value. Results from the 
quantification verified the initial hypothesis that with increasing MnCb 
concentrations, PCR yields would linearly decrease due to increasing errors, 
which cause Taq polymerase to slow the DNA amplification due to its 
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proofreading activity (Figure 20). Since the linear trend drops off after [MnCfe] 
0.25 mlvl, this concentration was hypothesized to correspond to the library with 
the optimal mutation frequency. Libraries corresponding to [MnCb] of 0.2, 0.25 
and 0.3 mM were digested with HincftU and Spel, ligated into pSub2-spe and 
transformed into chemically competent XL10-Gold bacteria yielding sampling 
spaces of 82,122 and 24, respectively, while the control ligation showed 3 vector 
religations. 
Ten unselected clones were chosen from the 0.25 and 0.3 mM MnCI2 
libraries and sent for sequencing. A 600 bp region of cap from pSub201 
nucleotide numbers Table 2. EP-PCR library mutation frequencies. 
o o e , o n c „ . [Manganese Chloride] (mM) -+ 0.25 0.3 
3364-3964 were used — ——-Base pairs sequenced 
for analysis with the Total Mutations 
Mutation frequency, % 
assumption that the Mutations per gene 
Mutation types, % 
mutational frequencies A_+T- T _ > A 
A->C, T->G 
in a small region would A - *G. T - > c 
G^A, C^T 
correlate with the G->C, C->G 
G^T, C^A 
statistics of the overall Frameshift 
600 
95 
1.57 + 0.65 
41.17 + 16.8 
23 
6 
34 
6 
1 
3 
26 
600 
112 
1.87 + 0.63 
48.5 + 16.5 
22 
5 
39 
8 
3 
4 
18 
2600 bp gene. Mutation frequencies of the 0.25 mM and 0.3 mM libraries were 
1.57 + 0.65 and 1.87 + 0.63, respectively, which led to much greater than the 
desired ~ 2-5 nucleotide change per gene (Table 2). The actual mutations in the 
sequenced clones are shown in Table 3 with consistently occurring mutations 
italicized. I hypothesized that these frequent mutations were either hot spots in 
the DNA or correlated to error in the gold standard sequence used for 
comparison. An error in the gold standard was deemed the reason for the 
recurring mutations, and they were removed from the analysis. 
Table 3. Mutations found in sequenced library clones. 
Clone 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0.25 mM MnCI2 
A3928T, A3513G, A3858G, A3899G, 
A3918G, A3946G, C3764G, G3897A, 
G3761C 
A3313T, A3773T, A3842T, A3858G, 
delA3900, C3660T, C3764G, G3897A, 
G3761C, T3514A, T3509C, T3825C 
A3441G, A3858G, A3867G, A3887G, 
A3902C, A3906C, delA3796, delA3894, 
delA3900, delA3946, insA3782, C3764G, 
delC3901, G3765A, G3897A, G3761C, 
delG3921,T3588C 
A3468T, A3791T, A3808T, A3388G, 
A3858G, A3894G, A3899G, delA3849, 
delA3903, C3452A, C3651T, C3764G, 
G3897A, G3761C, insT3930 
A3655G, A3780G, A3858G, delA3900, 
C3764G, G3897A, G3761C 
A3313T, A3861T, A3987T, A3365G, 
A3435G, A3844G, A3858G, A3899G, 
A3872C, delA3733, C3764G, G3897A, 
G3761C, T3638A, T3534C, T3929C 
A3555T, A3724T, A3523G, A3554G, 
A3670G, A3853G, A3858G, A3876G, 
A3493C, delA3900, insA3929, C3757T, 
C3764G, insC3949, G3792A, G3897A, 
G3761C, T3409C, insT3934 
A3513T, A3858G, delA3900, C3764G, 
insC3949, G3897A, G3761C, insG3956, 
T3399A, T3702A, insT3934 
A3532T, A3688T, A3542G, A3662G, 
A3858G, A3925C, delA3900, C3408A, 
C3764G, G3661A, G3897A, G3761C, 
delG3736, T3552A 
A3753T, A3641G, A3858G, A3892G, 
A3899G, C3756A, C3764G, G3897A, 
G3761C, G3898C, delG3492, T3553A, 
T3378G 
0.30 mM MnCI2 
A3773T, A3859T, A3698G, A3784G, A3858G, 
A3480C, A3836C, delA3628, delA3900, 
C3660T, C3764G, insC3949, G3508A, 
G3897A, G3481C, G3761C, T3585C, 
T3746C, T3799C.T3913C 
A3374T, A3721T, A3858G, A3902C, 
delA3887, del3894, delA3900, delA3961, 
insA3784, C3644A, C3764G, delC3901, 
G3559A, G3897A, G3761C, insG3932 
A3463T, A3472T, A3567T, A3547G, A3575G, 
A3665G, A3717G, A3858G, A3899G, 
C3495A, C3731T, G3764G, G3481A, 
G3897A, G3761C, G3898C, delG3771, 
T3499A, T3590C, T3716C 
A3513T, A3954T, A3851G, A3858G, A3865G, 
delA3900, C3525A, C3550T, C3764G, 
G3897A, G3761C 
A3624T, A3669G, A3858G, A3878G, 
A3899G, A3945G, insA3797, C3764G, 
G3897A, G3761C, T3664C 
A3576T, A3859T, A3925T, A3484G, A3665G, 
A3670G, A3858G, A3899G, A3685C, 
C3764G, G3897A, G3761C, G3792T, 
insG3932, T3908A, T3488C 
A3968T, A3532G, A3555G, A3858G, 
A3906G, delA3778, delA3900, C3617T, 
C3764G, delC3779, G3367A, G3449A, 
G3897A, G3761C, G3814T, T3573A, 
T3751C, T3385G 
A3423T, A3561T, A3567T, A3852T, A3419G, 
A3780G, A3858G, A3867G, A3899G, 
C3764G, G3897A, G3761C, T3398A, 
T3645A, T3446C, T3863C 
A3583G, A3858G, A3883G, A3892G, 
A3952G, delA3900, C3764G, G3897A, 
G3761C, insG3616, T3933C, T3502G 
A3414T, A3628T, A3693G, A3858G, A3866G, 
delA3900, C3764G, G3897A, G3761C, 
T3645C, T3941C 
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Kellie McConnell and I have isolated the 
2.6 kb cap genes from AAV serotypes 2, 7, 8 and 
9 that will serve as the templates for DNA shuffling 
(Figure 21). These constructs were isolated from 
the hybrid pBluescript/cap constructs by digesting 
with Sg/ll and Pvul 
Figure 21. Cap genes 
from AAV serotypes 
3.3 Developing in vitro cell system 2,7,8,9 are shown. 
I have developed the target/non-target co-culture cell system. Since the 
NHDF cells are a primary line, which are more sensitive to media requirements, I 
successfully attempted growing the HeLa cells with the NHDF growth conditions. 
A stain for cell surface markers capable of differentiating the cancerous from 
noncancerous cells was desired to verify that the cell type surfaces did not 
change when introduced into a co-culture. P16, a tumor suppressor gene, is 
overexpressed in multiple cancers and was chosen as the first cell surface 
marker. In the HeLa cervical cancer cell line, human papillomavirus infection 
leads to E7 protein expression, which inactivates retinoblastoma protein leading 
to p16 overexpression [62]. I first labeled a p16 antibody with 5 ug/mL 
AlexaFluor 568 dye and subsequently stained both the HeLa and NHDF cells 
grown in their respective media with both antibody and DAPI (Figure 22). 
36 
HeLa Cells NHDF Cells 
Figure 22. p16 antibody and DAP I cell labeling is shown for HeLa cells (a,c) and NHDF ceils 
(b,d) with images taken under settings optimized for each cell type. 
I have also begun generating a stable GFP-expressing HeLa cell line. 
Using a lipofectamine transfection, I first introduced a GFP plasmid into the cells. 
Next, I subjected the cells to selection concentrations of G418 ranging from 0-
1100 ug/mL. Selection concentrations of 800-1100 ug/mL were successful in 
killing all non-transfected cells, yielding populations of GFP-expressing HeLa 
cells. 
Fluorescence activated cell sorting (FACS) between GFP-expressing 
populations of HeLa cells and non-GFP-expressing populations was performed 
on mixed cultures (Figure 23). Control cell GFP levels were defined by the 
P1/P4 area of the control graphs while outliers were sorted into the GFP 
population as defined by P2 in the sample graphs. Cells with borderline GFP 
levels as shown in purple in (d) were discarded to avoid error. 
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Figure 23. FACS controls (a,b) and results (c,d) are shown. 
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